BioSpace News Archive

Cidara Therapeutics, Inc. announced that on May 14, 2024 it received a letter from the Listing Qualifications Department staff of the Nasdaq Stock Market LLC notifying the Company that it has regained compliance with Nasdaq’s requirements for continued listing.

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended March 31, 2024, and provided recent pipeline and business updates.

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the first quarter ended March 31, 2024 and other recent business developments.

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies in oncology that address cancer immune resistance, announced today financial results for the three months ended March 31, 2024 and provided a corporate update.

NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024.

Apogee Therapeutics, Inc. announced that it has initiated dosing in the Phase 2 trial of APG777 in patients with moderate-to-severe atopic dermatitis.

Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate highlights.

Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q2 FY 2024”) and six months (“YTD FY 2024") ended March 31, 2024.

Eyenovia, Inc., a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, announced its financial and operating results for the first quarter ended March 31, 2024.

Monte Rosa Therapeutics, Inc. announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock.